Proteasome activator complex subunit 3

2007 ◽  
Author(s):  
Ruiwen Zhang
Keyword(s):  
Proteasome Activator ◽  
Activator Complex

Proteasomes

2005 ◽  
Vol 41 ◽  
pp. 31-48 ◽  
Author(s):  
Burkhardt Dahlmann
Keyword(s):  
Immune Response ◽  
Polyubiquitin Chains ◽  
Proteasome Activator ◽  
Peptide Epitopes ◽  
Protein Substrates ◽  
Substrate Protein ◽  
System A ◽  
Intracellular Proteins ◽  
Proteolytic Chamber ◽  
Activator Complex

The major enzyme system catalysing the degradation of intracellular proteins is the proteasome system. A central inner chamber of the cylinder-shaped 20 S proteasome contains the active site, formed by N-terminal threonine residues. The 20 S proteasomes are extremely inefficient in degrading folded protein substrates and therefore one or two multisubunit 19 S regulatory particles bind to one or both ends of the 20 S proteasome cylinder, forming 26 S and 30 S proteasomes respectively. These regulatory complexes are able to bind proteins marked as proteasome substrates by prior conjugation with polyubiquitin chains, and initiate their unfolding and translocation into the proteolytic chamber of the 20 S proteasome, where they are broken down into peptides of 3–25 amino acids. The polyubiquitin tag is removed from the substrate protein by the deubiquitinating activity of the 19 S regulator complex. Under conditions of an intensified immune response, many eukaryotic cells adapt by replacing standard 20 S proteasomes with immuno-proteasomes and/or generating the proteasome activator complex, PA28. Both of these adaptations change the protein-breakdown process for optimized generation of antigenic peptide epitopes that are presented by the class I MHCs. Hybrid proteasomes (19 S regulator–20 S proteasome–PA28) may have a special function during the immune response. The functions of other proteasome accessory complexes, such as PA200 and PI31 are still under investigation.

scholarly journals Proteasome activator complex PA28 identified as an accessible target in prostate cancer by in vivo selection of human antibodies

2013 ◽  
Vol 110 (34) ◽  
pp. 13791-13796 ◽  
Author(s):  
David Sánchez-Martín ◽  
Jorge Martínez-Torrecuadrada ◽  
Tambet Teesalu ◽  
Kazuki N. Sugahara ◽  
Ana Alvarez-Cienfuegos ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Proteasome Activator ◽  
Human Antibodies ◽  
In Vivo Selection ◽  
Activator Complex ◽  
Selection Of

scholarly journals Expression and subcellular localization of mouse 20S proteasome activator complex PA28

FEBS Letters ◽  
1997 ◽  
Vol 413 (1) ◽  
pp. 27-34 ◽  
Author(s):  
Andrea Soza ◽  
Christine Knuehl ◽  
Marcus Groettrup ◽  
Peter Henklein ◽  
Keiji Tanaka ◽  
...  
Keyword(s):  
Subcellular Localization ◽  
20S Proteasome ◽  
Proteasome Activator ◽  
Activator Complex

scholarly journals High nuclear expression of proteasome activator complex subunit 1 predicts poor survival in soft tissue leiomyosarcomas

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Sha Lou ◽  
Arjen H. G. Cleven ◽  
Benjamin Balluff ◽  
Marieke de Graaff ◽  
Marie Kostine ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Poor Survival ◽  
Proteasome Activator ◽  
Nuclear Expression ◽  
Activator Complex

Specific MALDI Imaging and Profiling for Biomarker Hunting and Validation:  Fragment of the 11S Proteasome Activator Complex, Reg Alpha Fragment, Is a New Potential Ovary Cancer Biomarker

2007 ◽  
Vol 6 (11) ◽  
pp. 4127-4134 ◽  
Author(s):  
Remi Lemaire ◽  
Sonia Ait Menguellet ◽  
Jonathan Stauber ◽  
Valerie Marchaudon ◽  
Jean-Philippe Lucot ◽  
...  
Keyword(s):  
Cancer Biomarker ◽  
Maldi Imaging ◽  
Proteasome Activator ◽  
Ovary Cancer ◽  
Activator Complex
Sign in / Sign up

Export Citation Format

Share Document